GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » 3-Year RORE %

ANL (Adlai Nortye) 3-Year RORE % : 0.00% (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Adlai Nortye 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Adlai Nortye does not have enough data to calculate 3-Year RORE %.


Adlai Nortye 3-Year RORE % Historical Data

The historical data trend for Adlai Nortye's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adlai Nortye 3-Year RORE % Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23
3-Year RORE %
- - -

Adlai Nortye Quarterly Data
Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Jun24
3-Year RORE % Get a 7-Day Free Trial - - - - -

Competitive Comparison of Adlai Nortye's 3-Year RORE %

For the Biotechnology subindustry, Adlai Nortye's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adlai Nortye's 3-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adlai Nortye's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Adlai Nortye's 3-Year RORE % falls into.



Adlai Nortye 3-Year RORE % Calculation

Adlai Nortye's 3-Year RORE % for the quarter that ended in Jun. 2024 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( - )/( - )
=/
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2024 and 3-year before.


Adlai Nortye  (NAS:ANL) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Adlai Nortye 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Adlai Nortye's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Adlai Nortye Business Description

Traded in Other Exchanges
N/A
Address
685 US Highway 1, New Jersey Biotechnology Development Center, 2nd floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.